Please login to the form below

Not currently logged in

Aurobindo/ Diod generic venture in Russia

Aurobindo and Diod have established a joint venture to manufacture and sell generic pharmaceuticals in the markets of Russia, Belarus and Kazakhstan

Aurobindo Pharma and Ojsc Diod, a Russian manufacturer of ecological healthcare equipment and nutrition supplements, have announced a joint venture called the Aurospharma Company, which is to be established in Russia and will manufacture and sell generic pharmaceuticals in the markets of Russia, Belarus and Kazakhstan.

As part of this venture, Aurospharma intends to construct a state of the art plant in order to manufacture various drugs, mainly ones classified as over the counter (OTC) products in Russia. This includes non penicillin and non cephalosporin Rx generics. In addition, drugs such as penicillin and cephalosporins will also be sourced, in order to sell.

The plant to be built in Russia will focus on the production of socially significant medicinal drugs, therefore complying with the Strategy for Development of the Russian pharmaceutical industry. It will enable the Russian public healthcare system to be less dependent on the importing of finished dosage form, therefore creating substantial savings and making modern pharmaceuticals more affordable and accessible to the public within those countries.

It is expected that the construction will be completed and the plant will attain its rated capacity closer to the end of 2013.

8th September 2011


Featured jobs

Subscribe to our email news alerts


Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...